P
atients diagnosed with small to mediumsized vestibular schwannomas (VS) typically have several treatment options available to them including microsurgical resection, fractionated or single-fraction stereotactic radiation (SRS) or observation. Typically, in our experience, a myriad of factors influence which option any individual patient chooses for "treatment" of their VS. 1 One of the advantages of microsurgical resection of VS is the supposition that if completely removed, it will provide long-term cure. As summarized in a quote often attributed to Logan Clendening, MD, "Surgery does the ideal thing; it separates the patient from the disease. It puts the patient back to bed and the disease in a bottle." We recently showed, using the Surveillance, Epidemiology, and End Results database, that ∼10% of tumors with posterior fossa diameters <2.0 cm receive less than gross total resection (GTR) in the USA. Tumors ranging from 2 to 4 cm in diameter were not completely removed in ∼30% of operations in the USA between 2004 and 2011. 4 Additionally, several authors have lately shown a less than GTR, especially for a large tumor, may result in excellent postoperative facial nerve function. [5] [6] [7] Currently, a multisite, nonrandomized prospective study examining the results from planned subtotal resection of large VS followed by radiation is ongoing (NCT01129687) to try and further elucidate the advisability of this strategy. 8 We have previously published the results of long-term QoL in patients with VS comparing microsurgery, SRS, and observation. 9 The purpose of this analysis was to evaluate long-term quality of life (QoL) in a cohort of patients who received either GTR or less than GTR for VS (Figure) . It was our hypothesis that patients who underwent less than GTR would have better long-term QoL secondary to a less aggressive surgical approach.
METHODS

Operated Patients
All patients provided written informed consent to be included in this analysis, and the study was approved by the institutional review board at each participating institution. Two tertiary referral centers specializing in the treatment of VS enrolled patients for analysis, 1 in the USA and 1 in Western Europe. All patients at least 18 yr old diagnosed with sporadic VS less than 3.0 cm in posterior fossa diameter between 1998 and 2008 were included. No patient had undergone prior surgery or radiation, and no additional treatment such as SRS or further surgery has been performed on any of the patients included in this analysis. Furthermore, none of the patients had growing residual tumor that was being monitored. Thus, these patients represent 2 very selected cohorts of patients who have undergone only 1 operation as the sole treatment for their small-to medium-sized VS. Patients with neurofibromatosis type 2 were excluded.
Standard baseline demographic data including patient age, sex, tumor size, and surgical approach were recorded. Patients were determined to have GTR when the operating neurosurgeon and neurotologist independently agreed, the entire tumor was removed, and the first followup magnetic resonance imaging (MRI) scan, typically performed 3 mo postoperatively, showed no residual tumor. Strict imaging criteria were followed to differentiate any tiny residual tumor from expected linear postoperative enhancement often seen in the internal auditory canal (IAC), for instance, on postoperative imaging. 10 Any nodular enhancement was considered to represent residual tumor if it was in the location of the tumor as it appeared on the preoperative MRI scan. 10, 11 Less than GTR occurred when it was agreed by the operating team that tumor was left at the time of surgery or there was nodular enhancement seen on the postoperative MRI. In patients who received less than GTR, the tumor remnant was small (less than 1.5 cc) and followed the course of the facial nerve. No remnant showed convincing growth during the follow-up period. Audiometric data were recorded before and after surgery according to the 1995 American Academy of OtolaryngologyHead and Neck Surgery (AAO-HNS) Committee reporting guidelines. 12 Pre-and postoperative facial nerve function was recorded using the House-Brackmann (HB) grading scale. 13 All operations are undertaken with the goal of achieving GTR. However, primarily, when the facial nerve is found to be extremely attenuated and adherent to the tumor, or rarely if the tumor cannot be dissected free from the brainstem or critical neurovasculature, a small remnant is left in Situ to try and preserve these structures and avoid permanent new neurological deficits. Intraoperative electrical testing of the facial nerve, as previously described, is often used to help guide when the resection should be halted.
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QoL Assessment
Patients undergoing microsurgical resection of their VS were queried via a postal questionnaire mailed to their homes with return envelope and postage provided. Patients in the USA received $30 upon return of their completed questionnaire, and nonresponders were contacted 1 time per institutional review board (IRB) protocol to try and maximize return rate. The details of the QoL assessment instruments are previously reported. 9 Briefly, to compare long-term QoL in patients following microsurgery they completed the Short Form Health Survey-36 (SF-36), the Patient-Reported Outcomes Measurement Information System (PROMIS-10), the Glasgow Benefit Inventory (GBI), and the disease specific Penn Acoustic Neuroma Quality of Life (PANQOL) scale.
The SF-36 is a widely used general QoL assessment tool that consists of 36 questions which are weighted to provide a summary score of 0 (worst QoL) to 100 (best QoL). 15 For the purposes of this analysis, we specifically analyzed the physical and mental health subscores. Similarly, the PROMIS-10 (www.nihpromis.org) asks general QoL questions that allow for a physical and mental health subscore with a higher value once again indicating better QoL. The GBI was developed to assess change in QoL based on an intervention, in this case microsurgery to remove VS, and was designed specifically to address otorhinolaryngological disease processes. 16 In addition to a total score, this instrument includes subscores for general health, social support, and physical health. Scores range from -100 indicating maximum decline in QoL to +100 indicating maximum benefit from the intervention. The PANQOL is the only disease-specific validated QoL instrument for VS. It includes 26 items and subscores of hearing, balance, facial function, pain, anxiety, energy, and general health, which cumulatively result in a PANQOL total score of 0 (worst QoL) to 100 (best QoL).
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Statistical Analysis
Continuous features were summarized with means, medians, and interquartile ranges (IQRs); categorical features were summarized with frequency counts and percentages. Comparisons of baseline features, facial nerve and hearing outcomes, and QoL outcomes between the 2 surgical groups were evaluated using 2-sample t, Wilcoxon rank sum, chisquare, and Fisher exact tests. Comparisons of QoL outcomes between the 2 surgical groups after adjusting for baseline features, including age, sex, tumor size and surgical approach, and facial nerve and hearing outcomes were evaluated using multivariable linear regression models.
Statistical analyses were performed using version 9.3 of the SAS software package (SAS Institute; Cary, North Carolina). All tests were 2-sided, and P values < .05 were considered statistically significant.
RESULTS
Patients
Seventy-nine percent of contacted patients who had undergone microsurgery for their VS and met inclusion criteria returned a completed questionnaire. There was no significant difference between responders and nonresponders regarding patient sex, tumor laterality or size, and hearing or facial nerve function at presentation or last follow-up (P > .05), although nonresponders were older compared to responders (P = .006). A total of 143 patients returned completed surveys a mean of 7.7 yr (median 7.7; IQR: 5.7-9.6) following microsurgical treatment of their VS. One hundred and twenty-two (85%) had undergone GTR and 21 (15%) had less than GTR. Fifteen patients were operated via a middle fossa approach, all of whom had intracanalicular tumors and GTR. Thirty-four had translabyrinthine surgery of whom 3 (9%) had less than GTR, and 94 patients underwent retrosigmoid resection of their VS of whom 18 (19%) had less than GTR.
The mean age for the GTR patients was 57.4 vs 58.5 yr in the less than GTR group (P = .68). Women represented 62% of the GTR patients and 52% of the less than GTR group (P = .39). There was a significant difference in tumor size between the groups (Table 1) . Forty percent of tumors in the GTR cohort were intracanalicular or less than 1 cm in posterior fossa diameter compared to only 5% in the less than GTR patients. Moreover, 62% of patients in the less than GTR cohort had tumors between 2 and 3 cm in posterior fossa diameter, the largest size category in this analysis, compared to 19% in the GTR group (P < .001).
Hearing and Facial Nerve Function
No patient in the less than GTR cohort retained hearing in the operated ear. Ten percent of the patients in the GTR group had class A or B hearing at last follow-up (Table 1) , which was not statistically significant (P = .20). In other words, less aggressive tumor removal did not translate into better hearing outcomes and was never the primary reason to undertake less than GTR.
Long-term facial nerve function was likewise not significantly different between the 2 groups, although there was actually a trend towards worse facial nerve function in the less than GTR patients. In general, overall facial nerve function was very good in both groups. Ninety-one percent of patients undergoing GTR had HB grade 1 or 2 function almost 8 yr following removal of their tumor and 75% of the patients having less than GTR were HB grade 1 or 2. Of note, the remaining 25% of patients in the less than GTR cohort were HB grade 3. One patient each was HB grade 4, 5, and 6 in the GTR group (Table 1) . Facial nerve function was analyzed as a continuous variable comparing HB grade 1 to 6 (P = .097) as well as a categorical variable comparing HB grade 1 (normal facial nerve function) in each cohort to HB grade 2 to 6 (not normal facial nerve function; P = .15). Similar to hearing, leaving some tumor did not result in better objective long-term facial nerve function in this small, highly selected series of patients.
QoL Analysis
The primary goal of this study was to evaluate long-term QoL in patients with tumors less than 3.0 cm in posterior fossa diameter who undergo microsurgical treatment of their tumors comparing degree of resection. The results of the four different QoL assessments are shown in Table 2 . There were no statistically significant differences in GBI total score or subscores between the GTR and less than GTR patients. Also, there was no significant difference in the SF-36 physical subscore. However, there were statistically significant differences in the PROMIS-10 physical and mental subscores favoring GTR, and a significantly better SF-36 mental score also favoring GTR. In univariable analysis, consistent with a trend toward better facial nerve function, there was a significantly better PANQOL facial subscore in the GTR group. Also, there were slightly better PANQOL energy and general health subscores for the GTR cohort. The remaining PANQOL subscores of balance, hearing, pain, and anxiety, and the total PANQOL score were not significantly different whether the entire tumor was removed or not (Table 2) .
On multivariable analysis, after adjusting for baseline differences in age at survey, sex, tumor size, surgical approach, hearing and facial nerve function at last follow-up, there was a significant benefit to GTR when assessing long-term QoL based on SF-36 physical and mental subscores, PROMIS-10 physical and mental subscores, and the disease-specific PANQOL facial, energy, general health, and total scores ( Table 3 ). The benefit was still apparent even when only adjusting for tumor size differences in the multivariable model.
DISCUSSION
In this analysis of 143 patients undergoing microsurgical removal of a VS less than 3.0 cm in posterior fossa diameter, 15% of patients received less than GTR. In every case, this was due to the facial nerve becoming extremely splayed out and adherent to the tumor capsule, such that the operating surgeons felt that continuing the resection would likely result in unacceptable (HB grade 3 or higher) long-term facial nerve function. Recent preliminary results from the Acoustic Neuroma Subtotal Resection study have shown good facial nerve outcomes even in large tumors. 18 We anxiously await the final results of this important analysis to assess the outcomes of patients receiving both surgery and radiation for large VS. It was not the purpose of our study to specifically address the important question of whether improved facial nerve or hearing outcomes could be obtained by performing an intentional subtotal resection of VS.
The surgeons at both participating institutions who contributed data to the current study began every VS operation with the goal of GTR. There was no statistical difference in long-term facial nerve or hearing outcomes in our patients who had GTR vs less than GTR. Moreover, no patient in the less than GTR group experienced worse than HB grade 3 long-term function. Interestingly, there tended to be worse facial nerve function in the less than GTR group with, for instance, 80% of patients in the GTR cohort having normal (HB grade 1) facial nerve function compared to 65% in the less than GTR patients. Once again, this was not statistically significant, but is likely an indication that we "pushed" the resection to the maximum towards achieving our previously stated surgical goals.
Not surprisingly, considering the 2 cohorts objectively look very similar on average almost 8 yr after surgery, we did not find many differences on univariable analysis of patient-reported QoL assessments between patients who underwent GTR vs less than GTR. The only significant differences as outlined in Table 2 are that patients in the GTR group who scored significantly better on the SF-36 mental health, PROMIS-10 mental health and physical health, and the PANQOL facial and energy subscores. We feel the better PANQOL facial subscores can be explained by slightly better, although nonsignificant, facial nerve outcomes in patients who had all their tumors removed. There is no obvious reason why patients may score better on the energy subscale following GTR. Perhaps, it is a reflection of better overall mental health subscores translating into a better sense of well-being and thus energy? However, if this were the sole explanation, one might also expect significantly better scores on the anxiety subscale. It is possible that the anxiety subscale underperforms in detecting clinically significant differences as, for example, we previously found no difference in anxiety subscores comparing patients who underwent microsurgery, radiation or observation, and a group of nontumor normal controls. 9 Most importantly, on multivariable analysis, patients who underwent GTR had significantly better SF-36 and PROMIS-10 mental and physical health subscores and PANQOL facial, energy, general health, and total scores. Thus, patients seemed to benefit in terms of overall QoL from having the tumor completely removed. This is most significant for the SF-36 mental health subscore. For instance, we a Parameter estimate (standard error) for GTR vs less than GTR after adjusting for age at survey, sex, size, surgical approach, recent ipsilateral AAO-HNS, and recent HB in a multivariable linear regression model. The PE summarizes the direction and magnitude of the difference in QoL between the GTR vs less than GTR groups, while the SE summarizes the variability in this difference. For example, the PE of 6.4 for the SF36 physical score indicates that GTR patients had SF36 physical scores that were, on average, 6.4 points higher compared with less than GTR patients after adjusting for the covariates of interest. b Parameter estimate (standard error) for GTR vs less than GTR after adjusting for size only in a multivariable linear regression model.
recently calculated the minimum clinically important difference for the physical and mental health subscores of the SF-36. 19 We found that the minimum clinically important difference for the mental health subscore is 7 points. On both multivariable analyses, taking into account all potential differences between the 2 cohorts or just tumor size, patients in the GTR group scored 8 to 8.6 points higher compared to those who underwent less than GTR (Table 3) . Therefore, not only is there a statistically significant benefit to GTR according to mental health self-reported QoL scores almost 8 yr following surgery, but most importantly, a clinically significant advantage.
Why did the patients in this study who underwent GTR report better long-term QoL compared to patients who underwent less than GTR? The less than GTR patients did have significantly worse facial subscores on the PANQOL; therefore, we may be underestimating how this is driving QoL in these patients. Previous work we have done would argue, in fact, even moderate facial weakness is not a significant burden and should not be the factor accounting for the significant difference in general QoL outcomes. 20 There was no difference in any other complications between the 2 groups and no patient in either group has required additional treatment, so we hypothesize that there is a significant psychological benefit to patients who are radiographically cured of their VS, and this may translate into overall better QoL.
Along the same lines, considering the widespread acceptance of radiation and even observation for small-to medium-sized VS, it is quite possible that the subgroup of patients who elect to have microsurgery for their VS less than 3.0 cm are significantly, psychologically biased to "need" to have their tumors removed. This is why they chose microsurgery in the first place. Thus, when they learn they still have residual tumor that could grow and cause additional symptoms or require additional treatment, this translates to significantly and clinically important worse mental health subscores of the general QoL instruments. It is worth emphasizing, all patients in this study could have elected to either undergo observation or SRS for their VS. In a prior publication, the authors examined how these different treatment modalities affect long-term QoL. 9 It was our collective anecdotal impression that patients who had mild to moderate facial weakness and less than GTR were actually more pleased with their outcomes compared to patients with GTR and that same degree of facial weakness. We thought if we were going to perform a less than GTR, when the surgical goal was GTR, patients may actually prefer at least some facial weakness postoperatively to demonstrate that we did push the limit of the resection, and then used good surgical judgment to stop the operation before inducing severe, permanent facial nerve injury. If patients had less than GTR and awoke with HB grade 1 function, perhaps we did not try hard enough? Also, if we achieved GTR but patients had any permanent weakness, even mild, it was perceived we did not do the operation well enough and there was some technical deficiency. Our results from these cohorts would suggest the opposite is true. Patients who undergo less than GTR scored lower on the general and disease-specific QoL analysis, especially the SF-36 mental health subscore. Not too surprisingly, they scored lower on the PANQOL facial subscore as there was a nonsignificant trend towards less than normal facial nerve function in this group.
CONCLUSION
Our results show that patients who undergo GTR of VS less than 3.0 cm in posterior fossa diameter enjoy statistically significant, and clinically significant, better long-term QoL compared to patients who receive less than GTR. This is most evident in the mental health subscore of the SF-36. We feel there is a significant psychological advantage to removing the entire tumor and this translates into better QoL. However, we still would not recommend knowingly sacrificing facial nerve function or causing any other significant new neurological deficit, such as stroke, to achieve GTR. We feel our strategy of attempting GTR and halting the resection based on intraoperative judgment and experience of the operating team, and electrophysiologic monitoring, is still the optimal microsurgery strategy for VS when that treatment modality is pursued. When less than GTR is the result, the postoperative care team should be aware that this may result in a significant psychological burden to the patient.
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